Sunoco Partners Marketing & Terminals L.P. v. Powder Springs Logistics, LLC

District Court, D. Delaware·Decided February 27, 2020·No. 1:17-cv-01390·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE SUNOCO PARTNERS MARKETING & _ ) TERMINALS L.P., ) Plaintiff, V. Civil Action No. 17-1390-LPS-CJB POWDER SPRINGS LOGISTICS, LLC, and MAGELLAN MIDSTREAM ) PARTNERS, L.-P., .) Defendants. REPORT AND RECOMMENDATION Pending before the Court in this patent infringement case is Defendants Powder Springs Logistics, LLC and Magellan Midstream Partners, L.P.’s (“Defendants”) Motion for Summary Judgment of Non-Infringement and Invalidity (the “Motion”). (D.I. 381) Defendants make a number of different arguments in support of this Motion; this Report and Recommendation will address the Motion only as it relates to Defendants’ argument that certain patent claims asserted by Plaintiff Sunoco Partners Marketing & Terminals L.P. (“Plaintiff”) are invalid as anticipated or obvious over certain prior art references.'! For the reasons that follow, the Court recommends that the Motion be DENIED in that respect. I. BACKGROUND Plaintiff alleges that Defendants infringe five of Plaintiff's patents. Those patents are United States Patent Nos. 9,494,948 (the “"948 patent”), 9,606,548 (the “"548 patent”), 9,207,686 (the ‘“'686 patent”), 6,679,302 (the “'302 patent”) and 7,032,629 (the “'629 patent”) (collectively, “the asserted patents” or “the patents-in-suit”). The asserted patents relate to systems and

l The Court will address (or has addressed, (see D.I. 453; D.I. 495)) the remaining portions of the Motion in other Reports and Recommendations.

methods for the automated blending of butane and gasoline. The instant Motion puts the following patent claims at issue: claims 3 and 8 of the '548 patent, claims 3 and 7 of the '948 patent, and claim 3 of the '302 patent. The Court hereby incorporates its summary of the technology at issue set out in its January 8, 2018 Report and Recommendation, (D.I. 68 at 1-8); further information about these subjects relevant to the pending Motion will be set out in Section IJ] below. The Court also incorporates its summary of the procedural background of this matter, as set out in its January 16, 2020 Report and Recommendation. (D.I. 447 at 2) i. STANDARD OF REVIEW A. Summary Judgment The Court hereby incorporates its prior discussion of the legal standards for resolving summary judgment motions, which was set forth in its January 16, 2020 Report and Recommendation. (/d. at 2-4) And because the Court’s decision on this summary judgment motion also implicates principles relevant to claim construction, the Court also hereby incorporates its discussion of the legal standards for claim construction found in its July 26, 2019 Report and Recommendation. (D.I. 321 at 2-5) B. Invalidity A patent granted by the United States Patent and Trademark Office (*PTO”) is presumed to be valid. 35 U.S.C. § 282(a); Microsoft Corp. v. i4i Ltd. P’ship, 564 U.S. 91, 190-03 2011). The rationale underlying this presumption of validity is that “the PTO, in its expertise, has approved the claim[.]” KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 426 (2007). The burden of proving invalidity rests with the patent challenger at all times, who must establish ¢ patent’s invalidity by clear and convincing evidence in order to prevail. Microsoft Corp., 564 U.S. at

100-14. Clear and convincing evidence places within the mind of the fact finder “an abiding conviction that the truth of [the] factual contentions are highly probable.” Procter & Gamble Co. v. Teva Pharms. USA, Inc., 566 F.3d 989, 994 (Fed. Cir. 2009) (quoting Colorado v. New Mexico, 467 U.S. 310, 316 (1984)). 1. Anticipation A patent claim is anticipated under 35 U.S.C. § 102(a) or (b) if: (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent, or (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States... 35 U.S.C. § 102.' To anticipate, a “reference must disclose each and every element of the claimed invention, whether it does so explicitly or inherently.” Jn re Gleave, 560 F.3d 1331, 1334 (Fed. Cir. 2009). This test mirrors, to some extent, the test for infringement, and “it is axiomatic that that which would literally infringe if later anticipates if earlier.” Bristol-Myers Squibb Co. v. Ben Venue Labs., Inc., 246 F.3d 1368, 1378 (Fed. Cir. 2001). In order to anticipate, however, a reference must enable one of skill in the art to make and use the invention without undue experimentation, Jn re Gleave, 560 F.3d at 1334, and must also “show all of the limitations of the claims arranged or combined in the same way as recited in the claims[,]” Net MoneyIN, Inc. v. VeriSign, Inc., 545 F.3d 1359, 1370 (Fed. Cir. 2008).

l The Court herein refers to the versions of 35 U.S.C. §§ 102-03 that were in force prior to the enactment of the Leahy-Smith America Invents Act, and which are applicable here. See, e.g., Solvay S.A. v. Honeywell Int'l Inc., 742 F.3d 998, 1000 n.1 (Fed. Cir. 2014).

2. Obviousness A patent claim is invalid as obvious under 35 U.S.C. § 103 “if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.” 35 U.S.C. § 103(a). “Obviousness is a question of law based on underlying factual findings: (1) the scope and content of the prior art; (2) the differences between the claims and the prior art; (3) the level of ordinary skill in the art; and (4) objective indicia of nonobviousness.” Kinetic Concepts, Inc. v. Smith & Nephew, Inc., 688 F.3d 1342, 1360 (Fed. Cir. 2012) (citing Graham vy. John Deere Co., 383 U.S. 1, 17-18 (1966)). A party seeking to invalidate a patent on the basis of obviousness must establish (by clear and convincing evidence) that a person of ordinary skill in the art (a “POSITA”’) would have been motivated to combine the teachings of the prior art references to achieve the claimed invention, and that the POSITA would have had a reasonable expectation of success in doing so. Id? WW. DISCUSSION Defendants seek summary judgment that U.S. Patent No. 3,530,867, issued on September 27, 1970 to Robert Hass (“Hass”), anticipates claims 3 and 8 of the '548 patent and renders

In determining what would have been obvious to a POSITA, the use of hindsight is not permitted. See KSR, 550 U.S.

Free access — add to your briefcase to read the full text and ask questions with AI

Sunoco Partners Marketing & Terminals L.P. v. Powder Springs Logistics, LLC, (D. Del. 2020).

Sunoco Partners Marketing & Terminals L.P. v. Powder Springs Logistics, LLC (Sunoco Partners Marketing & Terminals L.P. v. Powder Springs Logistics, LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Graham v. John Deere Co. of Kansas City
383 U.S. 1 (Supreme Court, 1966)
Colorado v. New Mexico
467 U.S. 310 (Supreme Court, 1984)
KSR International Co. v. Teleflex Inc.
550 U.S. 398 (Supreme Court, 2007)
Procter & Gamble Co. v. Teva Pharmaceuticals USA, Inc.
566 F.3d 989 (Federal Circuit, 2009)
In Re Gleave
560 F.3d 1331 (Federal Circuit, 2009)
Net MoneyIN, Inc. v. VeriSign, Inc.
545 F.3d 1359 (Federal Circuit, 2008)
Microsoft Corp. v. i4i Ltd. Partnership
131 S. Ct. 2238 (Supreme Court, 2011)
Ntp, Inc. v. Research in Motion, Ltd.
418 F.3d 1282 (Federal Circuit, 2005)
Kinetic Concepts, Inc. v. Smith & Nephew, Inc.
688 F.3d 1342 (Federal Circuit, 2012)
Solvay S.A. v. Honeywell International Inc.
742 F.3d 998 (Federal Circuit, 2014)
Iris Corporation v. Japan Airlines Corporation
769 F.3d 1359 (Federal Circuit, 2014)
Trustees of Columbia Univ. v. Symantec Corporation
811 F.3d 1359 (Federal Circuit, 2016)
Sincavage v. Barnhart
171 F. App'x 924 (Third Circuit, 2006)
Pfizer Inc. v. Teva Pharmaceuticals U.S.A., Inc.
882 F. Supp. 2d 643 (D. Delaware, 2012)
Henderson v. Carlson
812 F.2d 874 (Third Circuit, 1987)